38 completed, 14 unknown, 7 recruiting, 6 terminated. 75 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 75 | Completed 38, Unknown 14, Recruiting 7, Terminated 6, Not yet recruiting 5, Withdrawn 3, Active not recruiting 2 |
Follow Ankylosis: new trials by email Literature Review of Ankylosis trials Research Report on Ankylosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis Secukinumab (IL-17i ), Upadacitinib (JAKi) - Axial Spondyloarthritis (AxSpA) | Phase 4 | Not yet recruiting | The University of Texas Health Science Center, Houston | 40 | 2026-11-01 | 2026-10-14 |
| Ivarmacitinib With or Without Celecoxib for Ankylosing Spondylitis Ivarmacitinib with celecoxib, Ivarmacitinib Monotherapy - Ankylosing Spondylitis (AS) | Phase 4 | Not yet recruiting | Peking University Third Hospital | 138 | 2026-10-25 | 2026-10-27 |
| Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis Upadacitinib 15 MG [Rinvoq] - Axial Spondylarthritis (axSpA) | Phase 4 | Not yet recruiting | CARE ARTHRITIS LTD. | 200 | 2026-05-01 | 2026-02-06 |
| Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) Carotid Ultrasound, High-intensity lipid-lowering therapy, Standard care according to ESC 2021 guidelines - Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | Phase 4 | Recruiting | Instituto de Investigación Marqués de Valdecilla | 1944 | 2026-04-22 | 2026-11-10 |
| Effectiveness and Safety of Acemetacin in Active Axial Spondyloarthritis: A Real-world Study Acemetacin - Axial Spondyloarthritis, Axial Spondyloarthritis, Non-Radiographic | Phase 4 | Not yet recruiting | Chinese PLA General Hospital | 150 | 2026-04-01 | 2026-05-12 |
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases Dengue 1,2,3,4 (attenuated) vaccine - Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 477 | 2026-03-16 | 2026-07-20 |
| REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases JAKi dose reduction strategy, JAKi disease activity guided continuation of same dose strategy - Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | Phase 4 | Recruiting | Sint Maartenskliniek | 200 | 2025-09-15 | 2025-09-17 |
| Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis Etanercept, Benzathine Penicillin, Placebo - Spondyloarthritis (SpA), Ankylosing Spondylitis (AS) | Phase 4 | Recruiting | Nanfang Hospital, Southern Medical University | 340 | 2025-06-14 | 2025-06-26 |
| Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis Secukinumab, Adalimumab - Ankylosing Spondylitis | Phase 4 | Not yet recruiting | The Affiliated Hospital Of Guizhou Medical University | 10 | 2025-02-01 | 2025-02-18 |
| A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis Upadacitinib 15 MG [Rinvoq], Placebo - Psoriatic Arthritis, Spondyloarthritis, Axial | Phase 4 | Recruiting | CARE ARTHRITIS LTD. | 100 | 2024-12-03 | 2026-04-03 |
| A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis Secukinumab 300mg s.c., Secukinumab 150mg s.c. - Ankylosing Spondylitis (AS) | Phase 4 | Recruiting | Tongji Hospital | 100 | 2024-06-14 | 2026-01-27 |
| ToFAcitinib in Early Active Axial SpondyloarThritis: Tofacitinib 5 MG - Axial Spondyloarthritis | Phase 4 | Recruiting | Charite University, Berlin, Germany | 104 | 2023-11-10 | 2024-11-26 |
| Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Recombinant Herpes Zoster Vaccine (RZV), MTX Discontinuation, MMF Discontinuation - Rheumatoid Arthritis, Spondylitis, Ankylosing | Phase 4 | Active not recruiting | University of Sao Paulo General Hospital | 2005 | 2023-05-23 | 2026-05-04 |
| A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission Secukinumab, Placebo - Non-radiographic Axial Spondyloarthritis | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 240 | 2023-03-28 | 2026-10-14 |
| The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients Secukinumab 150 mg/ml, Adalimumab Ab, NSAID - Ankylosing Spondylitis | Phase 4 | Unknown | Qilu Hospital of Shandong University | 100 | 2022-03-15 | 2023-11-18 |
| REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) Adalimumab and its biosimilars, Biological: Etanercept and its biosimilars, Golimumab - Ankylosing Spondylitis, Axial Spondyloarthritis | Phase 4 | Unknown | Hanyang University Seoul Hospital | 448 | 2022-01-15 | 2021-12-20 |
| Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study Tofacitinib - Axial Spondyloarthritis | Phase 4 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 92 | 2022-01-01 | 2024-03-13 |
| Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis Tapered doses of TNFi, Standard dose of TNFi - Axial Spondyloarthritis | Phase 4 | Unknown | University Health Network, Toronto | 15 | 2021-12-01 | 2024-01-17 |
| Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS). Yuxuebi tablet, Placebo tablet - Ankylosing Spondylitis | Phase 4 | Unknown | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | 60 | 2021-07-01 | 2021-06-22 |
| Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy Eupatilin, Rebamipide - Rheumatoid Arthritis, Osteoarthritis | Phase 4 | Unknown | Seoul National University Boramae Hospital | 50 | 2021-06-01 | 2021-05-13 |
Showing 20 of 75. Sign in to see all of them.
Spondylitis, Ankylosing (59) · Axial Spondyloarthritis (18) · Arthritis, Rheumatoid (8) · Spondylarthritis (8) · Arthritis, Psoriatic (7) · Lupus Erythematosus, Systemic (3) · Non-Radiographic Axial Spondyloarthritis (3) · Spondylarthropathies (3) · Uveitis, Anterior (3) · Arthritis, Juvenile (2) · Myositis (2) · Osteoarthritis (2) · Scleroderma, Systemic (2) · Antiphospholipid Syndrome (1)
Joint Diseases (75) · Musculoskeletal Diseases (75) · Arthritis (74) · Bone Diseases (74) · Spinal Diseases (74) · Spondylitis (73) · Spondylarthropathies (71) · Spondylarthritis (66) · Axial Spondyloarthritis (56) · Skin and Connective Tissue Diseases (11) · Autoimmune Diseases (8) · Connective Tissue Diseases (8) · Immune System Diseases (8) · Rheumatic Diseases (8)
Etanercept (20) · Adalimumab (13) · Infliximab (12) · secukinumab (9) · golimumab (7) · Celecoxib (5) · Methotrexate (4) · Sulfasalazine (4) · Certolizumab Pegol (3) · Diclofenac (3) · upadacitinib (3) · Anti-Inflammatory Agents, Non-Steroidal (2) · Hydroxychloroquine (2) · Indomethacin (2) · Pamidronate (2)
Merck Sharp & Dohme LLC (6) · Wyeth is now a wholly owned subsidiary of Pfizer (6) · Sun Yat-sen University (5) · Pfizer (4) · Charite University, Berlin, Germany (3) · Nanfang Hospital, Southern Medical University (3) · Novartis Pharmaceuticals (3) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (2) · CARE ARTHRITIS LTD. (2) · Chinese University of Hong Kong (2) · Chung Shan Medical University (2) · Gu Jieruo (2) · University Hospital, Tours (2) · University of Sao Paulo General Hospital (2) · AbbVie (1)
China (17) · Germany (9) · France (8) · Netherlands (6) · United States (6) · Finland (5) · Poland (5) · Brazil (4) · Czechia (4) · Denmark (4) · Hungary (4) · Spain (4) · Taiwan (4) · Canada (3) · Italy (3)
Jieruo Gu, Prof (3) · Walter Maksymowych, Dr. (2) · Bogdan Batko, MD, PhD (1) · Denis Poddubbnyy, Prof. Dr. med. (1) · Denis Poddubnyy, Prof. Dr. (1) · Edmund K Li, MD (1) · Fernando M. Pimentel-Santos, MD, PhD (1)
PMID 38488976, PMID 19740906, PMID 21317434, PMID 21341463, PMID 21551511, PMID 21630245, PMID 21639907, PMID 21700683, PMID 22006544, PMID 22127697, PMID 22337244, PMID 22653382, PMID 24501241, PMID 25428762, PMID 26242443, PMID 26568588, PMID 27449221, PMID 28601821, PMID 28619118, PMID 28785857, PMID 28973650, PMID 30473179, PMID 31958280, PMID 33195311, PMID 33854572, PMID 36091030, PMID 36379575, PMID 38846755, PMID 39133200, PMID 39260856, PMID 40078463, PMID 41679320, PMID 41919656, PMID 41932224, PMID 41963078, PMID 42261247, PMID 42294825, PMID 42843284
2015 (4), 2017 (2), 2025 (2), 2005 (1), 2009 (1), 2016 (1), 2023 (1)